ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients

February 24, 2023

https://www.globenewswire.com/news-release/2023/02/24/2615064/0/en/ASLAN-Pharmaceuticals-Announces-Completion-of-Recruitment-in-Phase-2b-TREK-AD-Study-of-Eblasakimab-in-Atopic-Dermatitis-Patients.html

SAN MATEO, Calif. and SINGAPORE, Feb. 24, 2023 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (“ASLAN”, Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has enrolled the final patient in TREK-AD, a Phase 2b dose-ranging clinical study of eblasakimab in adults with moderate-to-severe atopic dermatitis (AD). ASLAN expects to report topline data from this study in early July 2023.

Read more at globenewswire.com

Related news for (ASLN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.